Key Highlights
- Palantir shares climbed approximately 9% during a five-day trading period amid heightened Middle East geopolitical activity.
- U.S. forces utilized Palantir’s platform to orchestrate a comprehensive strike involving 1,000 Iranian targets.
- The Department of Defense terminated Anthropic AI agreements citing national security issues, creating opportunities for Palantir.
- Fourth-quarter revenue jumped 70% year-over-year to reach $1.41 billion; domestic commercial sales expanded 137%.
- Analyst perspectives vary widely — price projections span from $46 (Burry’s assessment) to $260 (Bank of America’s forecast).
Palantir Technologies (PLTR) delivered impressive gains during the previous week, climbing nearly 9% over a five-session period. The upward movement coincided with geopolitical developments that highlighted the critical role of the company’s defense technology.
Palantir Technologies Inc., PLTR
Disclosures surfaced indicating that American military forces employed Palantir’s platform to orchestrate operations against approximately 1,000 Iranian locations. This type of mission-critical, battlefield application represents precisely the kind of validation that typically catalyzes investor interest.
Palantir currently maintains a framework agreement worth $10 billion with the U.S. Army alongside a $448 million Naval contract. News surrounding the Iran operations injected additional energy into an already robust government sector business.
An unexpected advantage materialized from within the Pentagon itself. Defense Department leadership instructed various agencies to discontinue utilization of Anthropic’s AI systems following disagreements concerning national security protocols. A six-month transition timeline has been established.
Rosenblatt elevated its PLTR price objective from $150 to $200 while maintaining a Buy recommendation on March 3, noting the transition period provides “ample time” to migrate toward LLMs supported by Palantir. The research firm emphasized that Middle Eastern conflicts underscore Palantir’s solution superiority compared to generic AI platforms.
Piper Sandler confirmed its Overweight stance with a $230 target price on the identical date, while acknowledging potential short-term operational challenges stemming from the Anthropic situation.
Financial Performance Continues to Impress
The underlying business metrics have been delivering remarkable results. During the latest reporting period, revenue accelerated 70% on a year-over-year basis to $1.41 billion. Domestic commercial revenue — representing enterprises deploying Palantir’s artificial intelligence capabilities — expanded 137%.
Management projects revenue exceeding $7 billion for 2026, representing a 61% climb from the previous year. This projection significantly surpasses consensus expectations from most Wall Street research teams.
Palantir’s “Rule of 40” metric — which combines growth velocity with profitability margins — registers at 127%, a figure that supporters cite as evidence the organization can expand operations while maintaining strong margins.
Valuation Concerns Persist Among Some
Skepticism remains among certain market participants. Michael Burry, celebrated for his “Big Short” investment thesis, has indicated Palantir’s intrinsic value might be closer to $46. The shares currently command a valuation exceeding 180 times earnings, a multiple he characterizes as unsustainable.
Goldman Sachs analyst Gabriela Borges maintains a measured outlook, while institutional stakeholders continue questioning whether Palantir can achieve its $7 billion revenue objective without experiencing volatility.
Conversely, Citi Research’s Tyler Radke and Bank of America’s Mariana Perez Mora have established price objectives of $255 and $260, respectively. Their analysis positions Palantir as the leading beneficiary of escalating defense and enterprise AI expenditures.
Drawing from 14 Buy recommendations, four Hold ratings, and two Sell opinions compiled during the past three months, PLTR receives a Moderate Buy consensus rating. The average price target across analysts stands at $191.76, suggesting approximately 22.6% appreciation potential from present trading levels.





